Inovio Pharmaceuticals(US:INO) Globenewswire·2026-02-17 02:45Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities during the specified Class Period, highlighting potential investor compensation opportunities [1][2]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, with a lead plaintiff deadline set for April 7, 2026 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, noting that many firms may lack the necessary experience [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Specifics - Inovio Pharmaceuticals is described as a biotechnology company focused on DNA medicines for diseases like HPV [5]. - The lawsuit alleges that Inovio made false or misleading statements regarding the manufacturing of its CELLECTRA device and the prospects of its INO-3107 Biologics License Application, which were overstated [5].